Johnson & Johnson (NYSE:JNJ) Shares Sold by Cable Hill Partners LLC

Cable Hill Partners LLC lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 11.2% in the first quarter, HoldingsChannel reports. The firm owned 7,038 shares of the company’s stock after selling 886 shares during the period. Cable Hill Partners LLC’s holdings in Johnson & Johnson were worth $1,100,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Lantz Financial LLC lifted its holdings in Johnson & Johnson by 3.3% during the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company’s stock worth $1,986,000 after buying an additional 377 shares during the last quarter. Sulzberger Capital Advisors Inc. bought a new position in Johnson & Johnson during the 4th quarter worth approximately $453,000. Joel Isaacson & Co. LLC lifted its holdings in Johnson & Johnson by 3.5% during the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company’s stock worth $12,294,000 after buying an additional 2,526 shares during the last quarter. State of Wyoming lifted its holdings in Johnson & Johnson by 205,580.0% during the 4th quarter. State of Wyoming now owns 10,284 shares of the company’s stock worth $1,487,000 after buying an additional 10,279 shares during the last quarter. Finally, Range Financial Group LLC lifted its holdings in Johnson & Johnson by 18.9% during the 1st quarter. Range Financial Group LLC now owns 15,886 shares of the company’s stock worth $2,635,000 after buying an additional 2,529 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 6.2%

Shares of JNJ stock opened at $164.78 on Thursday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The stock has a market cap of $396.47 billion, a PE ratio of 18.33, a price-to-earnings-growth ratio of 2.12 and a beta of 0.41. The business’s fifty day moving average is $153.95 and its 200-day moving average is $154.71. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The company had revenue of $23.74 billion for the quarter, compared to analysts’ expectations of $22.85 billion. During the same period last year, the firm earned $2.82 EPS. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. Equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.16%. Johnson & Johnson’s payout ratio is 57.84%.

Analysts Set New Price Targets

A number of research firms have commented on JNJ. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Bank of America dropped their price target on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a research report on Thursday, April 10th. Leerink Partners cut Johnson & Johnson from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Benchmark upgraded Johnson & Johnson to a “strong-buy” rating in a research report on Thursday, April 24th. Finally, Wall Street Zen upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 21st. Eleven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $171.00.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.